Pharma BD Deal Intelligence
A win taking shape: Takeda's $4B-upfront, up-to-$6B buy of Nimbus's TYK2 program delivered in December 2025 when zasocitinib hit both co-primary endpoints in Phase 3 psoriasis and beat apremilast on every ranked secondary — though the $2B in sales milestones still await an actual NDA filing.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Takeda will pay 4 billion dollars upfront and up to 2 billion in sales milestones to acquire Nimbus Therapeutics' TYK2 inhibitor subsidiary, the Japanese…
Takeda Pharmaceutical said on Tuesday it would acquire the TYK2 inhibitor program of Nimbus Therapeutics in a deal worth up to 6 billion dollars, paying…
Phase 3 plaque-psoriasis topline (Dec 18 2025): zasocitinib (TAK-279) met co-primary endpoints sPGA 0/1 and PASI 75 at wk16, superior to apremilast on ranked…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Takeda acquired Nimbus's TYK2 subsidiary (Nimbus Lakshmi) and its oral, highly selective allosteric TYK2 inhibitor NDI-034858 (TAK-279) for ~$4B upfront plus up to $2B in sales milestones (two $1B tranches at $4B and $5B annual net sales of TAK-279-derived products), total deal up to $6B. The deal was announced Dec 13, 2022 and closed Feb 8, 2023 after FTC clearance. The asset has since received the INN zasocitinib. In December 2025 Takeda reported positive topline results from two pivotal Phase 3 plaque-psoriasis studies: zasocitinib met both co-primary endpoints (sPGA 0/1 and PASI 75 at week 16) and beat active comparator apremilast on all ranked secondary endpoints, with ~70% of patients achieving clear/almost-clear skin (sPGA 0/1). Zasocitinib is also in Phase 3 development for psoriatic arthritis. Takeda plans to begin a U.S. NDA and other regulatory submissions in fiscal year 2026 — validating the deal thesis of acquiring a late-stage oral immunology asset positioned against the multi-billion-dollar TYK2/oral-psoriasis market.
7.5M US cases/yr · $25.0B Global plaque psoriasis biologics + oral market 2022 · ~$6B Total deal value (up to, incl. $2B sales milestones)
The Takeda-Nimbus Lakshmi acquisition centers on TAK-279 (NDI-034858, formerly), an oral allosteric TYK2 inhibitor with lead Phase 3 indications in moderate-to-severe plaque psoriasis (~7.5 million U.S. adults) and psoriatic arthritis (~1.5 million U.S. adults), plus follow-on programs in inflammatory bowel disease (Crohn's, ulcerative colitis; ~3 million combined U.S. patients) and systemic lupus erythematosus (~322,000 U.S. patients). Plaque psoriasis is the commercial anchor — a $25B global immunology market dominated by IL-23 and IL-17 biologics. The strategic premise of allosteric TYK2 inhibition is to deliver biologic-like efficacy with the convenience of an oral once-daily small molecule, replicating BMS's Sotyktu (deucravacitinib) commercial template. Nimbus's NDI-034858 is differentiated by superior PSO efficacy in Phase 2b — 67% PASI 75 at 12 weeks for the highest dose versus Sotyktu's PSO-1 PASI 75 of approximately 58% at 16 weeks (cross-trial). Pricing benchmarks for oral immunology drugs range $50K-75K per year WAC. Takeda's $4B upfront plus $2B milestones positions TAK-279 as a potential pipeline-anchor next-generation oral immunology asset, with peak sales consensus estimates ranging from $2-6B depending on indication breadth.
The plaque psoriasis competitive landscape is structured by mechanism class. The IL-23 biologic class is led by Skyrizi (risankizumab, AbbVie) — over $7B 2023 sales — and Tremfya (guselkumab, J&J) at over $3B; the IL-17 class includes Cosentyx (secukinumab, Novartis) at over $5B and Taltz (ixekizumab, Lilly) at over $2.5B. The TYK2 oral class was opened by Sotyktu (deucravacitinib, BMS) approved September 2022, BMS's flagship next-gen immunology bet replacing Otezla post-divestiture. Other oral entrants include Otezla (apremilast, Amgen, PDE4i, declining) and JAK inhibitors Rinvoq (upadacitinib, AbbVie) and Cibinqo (abrocitinib, Pfizer) — though JAK class growth is constrained by the 2021 FDA black box warning. TAK-279 (Nimbus/Takeda) is the second TYK2 inhibitor to reach Phase 3 with potential differentiation on selectivity, dosing, and breadth across PSO/PsA/IBD. Other early TYK2 entrants include Alumis ESK-001 (Phase 2 PSO), VTX958 (Ventyx/Valda, Phase 2), and ICP-332 (InnoCare).
Acquisition of Nimbus's TYK2 subsidiary closed after FTC clearance; ~$4B upfront paid, up to $2B sales milestones remain.
Two pivotal Phase 3 studies hit sPGA 0/1 and PASI 75 at week 16, superior to apremilast on ranked secondaries; ~70% sPGA 0/1. Validates the acquired asset.
Takeda intends to begin regulatory submissions including a U.S. NDA for zasocitinib in plaque psoriasis starting fiscal year 2026; Phase 3 psoriatic arthritis program ongoing.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Nimbus Therapeutics (Lakshmi subsidiary, TYK2 program) (this deal) | 2022 | $6.0B | — |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2022 deals · Takeda Pharmaceutical Company Ltd. deals · Dermatology deals